Refsum Disease

Updated: Jun 24, 2016
  • Author: Robert A Schwartz, MD, MPH; Chief Editor: William D James, MD  more...
  • Print


Refsum disease (RD) is a neurocutaneous syndrome that is characterized biochemically by the accumulation of phytanic acid in plasma and tissues. Patients with Refsum disease are unable to degrade phytanic acid because of a deficient activity of phytanoyl-CoA hydroxylase (PhyH), a peroxisomal enzyme catalyzing the first step of phytanic acid alpha-oxidation. Refsum disease can be classified as a peroxisome biogenesis disorder. This category is inherited as an autosomal recessive trait and is characterized by altered peroxisome assembly, resulting in multiple peroxisome enzyme deficiencies, complex developmental sequelae, and progressive disabilities. [1] Infantile Refsum disease is a peroxisome biogenesis disorder. [2]

Refsum first described this disease in 1946. Peripheral polyneuropathy, cerebellar ataxia, retinitis pigmentosa, and ichthyosis are the major clinical components. The symptoms evolve slowly and insidiously from childhood through adolescence and early adulthood.



Refsum disease is a recessive disorder characterized by defective peroxisomal alpha-oxidation of phytanic acid. [3, 4, 5] Consequently, this unusual, exogenous C20-branched-chain (3,7,11,15-tetramethylhexadecanoic acid) fatty acid accumulates in blood and tissues. It is almost exclusively of exogenous origin and is delivered mainly from dietary plant chlorophyll and, to a lesser extent, from animal sources. Blood levels of phytanic acid are increased in patients with Refsum disease. These levels are 10-50 mg/dL, whereas normal values are less than or equal to 0.2 mg/dL, and account for 5-30% of serum lipids. Fatty acid‒mediated neurodegeneration merits further scrutiny. [6]

Phytanic acid replaces other fatty acids, including such essential ones as linoleic and arachidonic acids, in lipid moieties of various tissues. [7] This situation leads to an essential fatty acid deficiency, which is associated with the development of ichthyosis. [8] A Refsum disease gene, phytanoyl-CoA hydroxylase (PHYH), has been localized to band 10p13 between the markers D10S226 and D10S223. [9] Refsum disease is genetically heterogeneous, with up to 55% of cases not being linked to the PAHX gene locus at D10S547 to D10S223. Some patients have been found to carry a defect in perforin 7 (PEX7 defect). [10, 11]

Based on the above, it was proposed that adult Refsum disease could be divided into types 1 and 2, depending on which gene is defective. [12] Thus, Refsum disease, like other peroxisomal diseases, is a heterogeneous syndrome. Recently, a mouse model for Refsum disease (Phyh knockout mouse by targeted disruption of the PHYH gene). In humans, the PHYH gene is about 21 kb and consists of 9 exons and 8 introns. It encodes a protein of 38.6 kd. [13]

An infantile form of Refsum disease also exists and is an autosomal recessive disorder of peroxisomal biogenesis, leading to many biochemical abnormalities, including elevated plasma concentration of phytanic acid, pristanic acid, very long chain fatty acids, and C27 bile acids. The disease presents in the first year of life and manifests with developmental delay, visual and hearing disturbances, and dysmorphic features. Ichthyosis is an unusual symptom. [14, 15]




Refsum disease is rare, with just 60 cases published worldwide.


No racial predominance is reported.


Only male cases were reported initially; however, now, neither sex predominates.


Classic Refsum disease manifests in children aged 2-7 years; however, diagnosis usually is delayed until early adulthood. However, a patient was described with rare late-onset adult disease first evident at age 72 years. [16]  Infantile Refsum disease makes its appearance in early infancy.



Prognosis in untreated patients generally is poor. Dysfunction of myelinated nerve fibers and the cardiac conduction system leads to central and peripheral neuropathic symptoms, impaired vision, and cardiac arrhythmias. The latter frequently are the cause of death.

In early diagnosed and treated cases, phytanic acid decreases slowly, followed by improvement of the skin scaling and, to a variable degree, reversal of recent neurological signs. Retention of vision and hearing are reported. Attenuation of neurologic, ophthalmologic, and cardiac symptoms requires constant adherence to a suitable diet and plasmapheresis.